Immuno-Biological Laboratories Co., Ltd.

As of March 31, 2026, Immuno-Biological Laboratories Co., Ltd. carries a market capitalization of 12.50B, placing it among publicly traded companies globally. Its enterprise value stands at 11.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Immuno-Biological Laboratories Co., Ltd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, Immuno-Biological Laboratories Co., Ltd. has 9.31M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Immuno-Biological Laboratories Co., Ltd. maintains a current ratio of 5.68, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Immuno-Biological Laboratories Co., Ltd.'s stock has gained approximately 107.92% over the past 52 weeks. The 50-day moving average sits at 1,092.90, while the 200-day moving average is 1,269.20.

As of March 31, 2026, Immuno-Biological Laboratories Co., Ltd. holds 989.47M in cash and equivalents against 177.09M in total debt, resulting in a net debt position of -812.38M. Total book value stands at 1.84B, with working capital of 1.29B providing operational flexibility.

Immuno-Biological Laboratories Co., Ltd.'s most recent stock split took place on September 26, 2013 with a 1:10 split ratio.